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Background  and  purpose      There  is  very  little  literature  on 
the  long-term  outcome  of  wrist  replacements. The  Norwegian 
Arthroplasty  Register  has  registered  wrist  replacements  since 
1994. We report on the total wrist replacements and their revision 
rates over a 16-year period.
Material and methods   189 patients with 189 primary wrist 
replacements (90 Biax prostheses (80 of which were cementless), 
23 cementless Elos prostheses, and 76 cementless Gibbon prosthe-
ses), operated during the period 1994–2009 were identified in the 
Norwegian Arthroplasty Register. Prosthesis survival was ana-
lyzed using Cox regression analyses. The 3 implant designs were 
compared and time trends were analyzed.
Results   The 5-year survival was 78% (95% CI: 70–85) and 
the 10-year survival was 71% (CI: 59–80). Prosthesis survival 
was 85% (CI: 78–93) at 5 years for the Biax prosthesis, 77% (CI: 
30–90) at 4 years for the Gibbon prosthesis, and 57% (CI: 33–81) 
at 5 years for the Elos prosthesis. There was no statistically signifi-
cant influence of age, diagnosis, or year of operation on the risk of 
revision, but females had a higher revision rate than males (RR = 
3, CI: 1–7). The number of wrist replacements performed due to 
osteoarthritis increased with time, but no such change was appar-
ent for inflammatory arthritis.
Interpretation   The survival of the total wrist arthroplasties 
studied was similar to that in other studies of wrist arthroplasties, 
but it was still not as good as that for most total knee and hip 
arthroplasties. However, a failed wrist arthroplasty still leaves the 
option of a well-functioning arthrodesis.
 
The body of literature on wrist arthroplasty is increasing, but 
most studies have dealt with a single prosthesis design or have 
compared  the  outcome  of  wrist  prosthesis  to  that  of  wrist 
fusion. Furthermore, most studies have been on rheumatoid 
patients. To our knowledge, no randomized trials comparing 
different designs have ever been published. 
Wrist arthroplasty with silicone implants was first popular-
ized by Swanson in the 1960s (Swanson 1973). The early results 
of these were promising. Unfortunately, with longer follow-up, 
mechanical failure became apparent and severe inflammatory 
reaction caused by silicone disintegration ensued ( Smith et al. 
1985, Brase and Millender 1986, Jolly et al. 1992).
The second-generation wrist prostheses introduced in the 
1970s typically included two metal components that articu-
lated by means of a ball-and-socket or a hemispheric design 
(Meuli 1973, Volz 1976). Most of these prostheses were taken 
off the market because of problems of joint imbalance and 
dislocation (Lorei et al. 1997, Carlson and Simmons 1998, 
Vogelin and Nagy 2003).
The third-generation of wrist prostheses represents an effort 
to reconstruct the center of wrist motion in order to prevent 
imbalance and dislocation (Cavaliere and Chung 2008).
The results of total wrist arthroplasy in terms of prosthe-
sis survival have generally been poor compared to most other 
prostheses.  In  2  studies  in  which  the  Biax  prosthesis—a 
cementless  third-generation  implant—was  used,  the  5-year 
survival was found to be 83% (Cobb and Beckenbaugh 1996), 
and the 8-year survival was also 83% (Takwale et al. 2002).
In this study, we estimated the incidence, prosthesis sur-
vival,  and  causes  of  and  risk  factors  for  revision  of  wrist 
arthroplasties using data from the population-based Norwe-
gian Arthroplasty Register. 
Patients and methods
The Norwegian Arthroplasty Register (NAR) started to collect 
data on total hip replacements in 1987. In 1994, this register 
was extended to include all artificial joints (Havelin 1999). 
Individual reports are received from all 7 hospitals that per-
form total wrist replacements in the country (population: 4.8 
million). 406  Acta Orthopaedica 2011; 82 (4): 405–409
From 1994 through 2009, 189 primary total wrist replace-
ments were performed in 189 patients (Table 1). 3 types of 
wrist  prostheses  were  used:  “Biax”,  “Elos”,  and  “Gibbon” 
(Figure  1). The  Biax  prosthesis  (DePuy, Warsaw,  IN)  is  a 
3-component  prosthesis  consisting  of  distal  and  proximal 
porous-coated metal parts and a UHMW polyethylene sliding 
core. The Biax prosthesis was used in the period 1994–2005, 
and without cement in 80 of 90 cases. 
3 versions of the Elos prosthesis were used (Elos 1: n = 2; 
Elos 2: n = 6; and Elos 3: n = 15). The 3 versions were all 
preliminary types of the Gibbon prosthesis. Elos 1 had a short 
metacarpal screw which was fully threaded, as was the radial 
screw. In the later versions of the Elos prosthesis, the metacar-
pal screws were longer, the diameter smaller, and the threads 
lower. The Elos implants were used in the period 2000–2005 
and without cement in all cases.
The Gibbon prosthesis (Swemac, Linkoping, Sweden) was 
CE-marked  in  late  2005,  and  the  design  has  not  changed 
since.  The  Gibbon  prosthesis  changed  name  to  Motec  in 
2010, without any change to the prosthesis. The Gibbon has 
a  smaller  screw  diameter,  and  the  threaded  area  has  been 
changed compared to the Elos 3. The Gibbon prosthesis is a 
modular (4-component) prosthesis. The articulation is cobalt 
chrome-molybdenum  alloy  treated  with  chromium  nitride, 
and the stem is made of titanium alloy blasted and coated with 
Bonit—a resorbable calcium phosphate combination (Brush 
white). Gibbon prostheses were used from 2006 to the end of 
inclusion, and all were inserted without cement.
The diagnoses were grouped into “inflammatory arthritis” 
(I) (n = 116) comprising rheumatoid arthritis and psoriatic 
arthritis, and into “non-inflammatory arthritis” (NI) (n = 73) 
comprising primary osteoarthritis, post-fracture disorders, lig-
ament injuries, and joint destruction after infection. 
Statistics
The observation time was the time from the primary replace-
ment until revision, or until the end of the study or death. The 
date of death for the patients who died was obtained from 
Statistics Norway (www.ssb.no/english/). Median follow-up 
(observation) time was calculated using the reverse Kaplan-
Meier method (Schemper and Smith 1996).
A revision was defined as exchange or removal of the whole 
prosthesis or parts of the prosthesis.
We  used  the  Student  t-test  and  analysis  of  variance 
(ANOVA) to compare continuous variables. For comparison 
of categorical variables, Chi-square tests were used. All p-val-
ues were 2-tailed, and the significance level was set to 0.05. In 
the Kaplan-Meier survival curves, the endpoint was revision 
for any reason. The survival curves were presented with log-
transformed 95% confidence intervals (CIs) and a lower limit 
Table 1. Demography
A  B  C  D  E  F  G  H  I  J
Biax  90  89%  57 (28–77)  6  84  5  18 (1–46)  18  9.3 (0–11.6)
Elos  23  39%  55 (23–79)  23  0  2  12 (2–21)  10  4.6 (0.4–8.6)
Gibbon  76  58%  52 (17–79)  44  32  3  25 (9–49)  11  2.6 (0.1–4.0)
Total  189  71%  55 (17–79)  73  116  7  27 (1–70)  39  5.4 (0–11.6)
A  Type of prosthesis
B  No. of primary prostheses   
C Proportion of females 
D Mean age (range) 
E  Non-inflammatory group (n) 
F  Inflammatory group (n) 
G No. of hospitals 
H Mean operations per hospital (range)  
I  No. of revisions 
J  Median follow-up in years (range)
Figure 1. A. The Biax prosthesis.   B. The Gibbon prosthesis.Acta Orthopaedica 2011; 82 (4): 405–409  407
adjustment for the number of patients at risk (Dorey and Korn 
1987). The survival curves were ended at 10 years or when 5 
cases remained, whichever came first.
Differences in revision rates between groups were tested 
using the log-rank test. Cox multiple regression analyses were 
used to study relative risks (RRs; hazard rate ratios) of revi-
sion according to prosthesis type, diagnosis, age, and sex. All 
relative risks were adjusted for the other variables.
Poisson regression analysis was used to analyze trends in 
the incidence of wrist replacement procedures. These analy-
ses were performed based on annual population rates for the 
Norwegian population, obtained from Statistics Norway. The 
p-values given in the text correspond to values derived from 
these Poisson analyses. Analyses were done using SPSS soft-
ware version 15 and the program “R”.
Results
The annual number of total wrist replacements changed over 
time (Figure 2). A decrease in the number of arthroplasties due 
to inflammatory arthritis was found (p < 0.001), but operations 
due to noninflammatory arthritis increased (p < 0.001).
Type of prosthesis
The Biax prosthesis was used almost exclusively in patients in 
the I group (Table 1). The median follow-up time was longer 
for the Biax prosthesis (9.3 years) than for the Elos (4.6 years) 
and Gibbon (2.6 years) (p < 0.001). The Elos prosthesis was 
used exclusively in the NI group, and the Gibbon prosthesis 
was used in both groups.
Revision and survival 
39 (21%) of the 189 wrist prostheses were revised: 10 of 23 
Elos prostheses, 11 of 76 Gibbon prostheses, and 18 of 90 
Biax prostheses. 
The mean time until first revision was 9.1 (CI: 8.5–9.8) 
years. The overall 5-year and 10-year survival was 78% (CI: 
70–85) and 71% (CI: 59–80), respectively (Figure 3). Pros-
thesis survival was 85% (CI: 78–93) at 5 years for the Biax 
prosthesis, 77% (CI: 30–90) at 4 years for the Gibbon pros-
thesis, and 57% (CI: 33–81) at 5 years for the Elos prosthesis 
(Figure 3). 
Loosening of the distal component and pain were the most 
common reasons for revision (Table 2). For the Biax prosthe-
sis, the main causes of revision were aseptic loosening, incor-
rect axis, and pain. The main cause of revision of the Elos and 
Gibbon prostheses was aseptic loosening of the distal compo-
nent, but in 3 cases deep infection was the reason for revision 
of the Gibbon prosthesis. In no case was pain registered as the 
only cause of revision.
In the 39 patients who underwent revision, the procedures 
performed were: exchange of the distal component (n = 9), 
exchange of the proximal component (n = 3), exchange of the 
whole prosthesis (n = 2), and removal of prosthetic parts with-
Figure 2. Number of replacements over time, by diagnosis group. 
Figure  3. Total  and  prosthesis-specific  survival  (Kaplan-Meier)  with 
95% CI shown in red. 
30
25
20
15
10
5
0
1998 2000 2002 2004 2006 2008 2010
Operations
Noninﬂamatory
Inﬂamatory
Year
Table 2. Reasons for revision (more than one reason could be given)
Brand  Biax   Elos  Gibbon  Total
Loosening of proximal component  3  2    5
Loosening of distal component  8  8  5  21
Dislocation  2  —  —  2
Instability  3  —  —  3
Axis problems  7  —  1  8
Deep infection  1  —  3  4
Pain  7  1  2  10
Wear of liner  1  —  —  1
Total number of revisions  18  10  11  39408  Acta Orthopaedica 2011; 82 (4): 405–409
out replacement (n = 23). An unknown revision procedure was 
done in 2 wrists. 
Risk factors for revision
Females had higher revision rate than males (RR = 3, CI: 1–7). 
Age had no statistically significant influence on prosthesis sur-
vival (RR = 0.8 per 10 year, CI: 0.66–1.1). No statistically 
significant difference in survival was found for the patients in 
the two diagnosis groups (RR = 1.2, CI: 0
Only 7 hospitals in Norway performed wrist arthroplasty 
surgery. The number of procedures performed in each hospital 
during the observation period ranged from one to 70 prosthe-
ses. The revision rate was similar in hospitals that had per-
formed more than or less than 50 wrist arthroplasties.
Discussion
The 5- and 10-year survival rates of 78% and 71% are similar 
to those in other studies. In a study of 76 wrist replacements 
with the Biax prosthesis, the 8-year survival of the implant 
was found to be 83% (Takwale et al. 2002). The 5-year sur-
vival was also 83% in a study of 52 patients treated with the 
Biax prosthesis (Cobb and Beckenbaugh, 1996). The patients 
in these 3 studies were also similar to ours regarding age, sex, 
and diagnoses. 
Completeness of data 
The completeness of registration in the Norwegian Arthro-
plasty Register was recently evaluated by comparing it to the 
mandatory reporting of administrative data to the Norwegian 
Patient Register (NPR), and it was found to be 97% for hip 
replacements, 99% for knee replacements, 82% for all primary 
ankle replacements, but only 52% for wrist replacements. One 
explanation for the under-reporting could be that relative to 
the hip and knee, few wrist replacements are performed, and 
that for this reason reporting to the Arthroplasty Register is not 
so well established among wrist surgeons.
The magnitude of under-reporting is unclear, however, as 
the NBD code group (except for NBD 8) of the NOMESCO 
2006 coding system, which is used by the hospitals in their 
reports to the NPR, does not require it to be specified whether 
the prosthesis has been inserted in the radio-carpal joint or in 
other joints in the carpus. Also, the code NBD 99 applies to 
any prosthesis operation in the wrist or hand. Thus, the NPR 
data on wrist implants most probably also include data from 
implants in joints other than the radio-carpal joint (Espehaug 
et al. 2006). We have no reason to believe that there is any 
systematic under-reporting to the NAR. 
Time trends 
The  overall  incidence  of  reported  wrist  arthroplasties  was 
unchanged in Norway during the study period (Figure 3). The 
incidence of total wrist replacements increased with time in 
the NI group, but not in the I group. These findings are consis-
tent with a general trend in recent years, which has also been 
seen for other joints. More joint replacements are being per-
formed due to osteoarthritis, and less for inflammatory arthri-
tis (da Silva et al. 2003, Pedersen et al. 2005, Weiss et al. 2006, 
Fevang et al. 2007).
Risk factors for revision 
The only factor that statistically significantly influenced sur-
vival was sex: females had a 3-fold higher revision rate than 
males. We found that there was no difference in prosthesis sur-
vival in patients with different diagnoses, which is in accor-
dance with the results of previous studies on ankle prostheses 
(Spirt et al. 2004, Doets et al. 2006).
Prosthesis type and survival 
There  were  major  differences  between  the  prosthesis  types 
concerning  patient  demographics  and  inclusion  periods.  In 
the Elos group, three different prostheses were used in the 23 
patients; the numbers were too small to allow us to perform a 
meaningful comparison of the different versions. In the Elos 
group, only non-inflammatory wrists were included, and in 
the Biax group only inflammatory wrists were included. In 
the Gibbon group, there was a mixture of the two diagnostic 
groups. In addition, the number of patients with inflammatory 
joint disease in the Gibbon group was small. Furthermore, the 
3 versions of the Elos prosthesis were all preliminary types of 
the Gibbon prosthesis. For these reasons, and due to the small 
numbers, our results on differences between types should be 
interpreted with caution. Based on our findings, we cannot con-
clude that one type of prosthesis was superior to any another. 
The results of wrist arthroplasty are still inferior to those of 
knee and hip arthroplasty, and the function may not be substan-
tially better than with arthrodesis. Current evidence does not 
support widespread implementation of this procedure. 
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